Gilead to license generic version of hepatitis C drug Sovaldi

SHARE Gilead to license generic version of hepatitis C drug Sovaldi

Gilead Sciences has reached a deal with several generic drugmakers to produce cheaper versions of its popular, expensive hepatitis C drug Sovaldi for use in developing countries.

Gilead said Monday that the India-based drugmakers will make a generic version of Sovaldi, also known as sofosbuvir, and another investigational drug for distribution in 91 countries.

Sovaldi hit the U.S. market late last year, and Gilead has taken criticism over the $1,000-per-pill price attached to the drug, which has been hailed as a breakthrough treatment. A full course of treatment can cost $84,000.

Hepatitis C is a liver-destroying virus carried by an estimated 3 million to 4 million Americans. Until late last year, the standard treatments required taking up to 12 pills a day, alongside antiviral drug injections that can cause flu-like symptoms. That approach cured only about 75 percent of patients.

U.S. regulators approved Sovaldi last December, and it was quickly embraced by physicians based on its once-a-day pill regimen and increased effectiveness, curing between 80 percent and 90 percent of patients.

$1,000 pill now hepatitis C treatment of choice

AbbVie seeks OK for new hepatitis C drug

Abbott sells part of generic drugs business to Mylan for $5.3B

The drug is expected to generate several billion dollars in sales this year alone for Foster City, California-based Gilead. The drugmaker has said that Sovaldi’s costs for payers will be recouped over the long term as fewer patients suffer liver failure and transplant complications. It also has said it offers financial assistance to patients who cannot afford the drug and related insurance costs.

Even so, Congressional leaders have criticized the drug’s pricing, and some state-based Medicaid plans are scaling back access to the treatment.

Gilead Sciences Inc. did not detail the price on the generic version of Sovaldi to be sold in developing markets.

The Indian companies, which include Ranbaxy Laboratories Ltd. and Mylan Laboratories Ltd., will pay sales royalties to Gilead. They will receive a technology transfer that helps them start production quickly.

Gilead’s agreement also covers another treatment, a single tablet combination of sofosbuvir and another antiviral drug, ledipasvir. Regulators in both the United States and Europe are currently reviewing that combination.


The Latest
The fire began in the basement of a house in the 4000 block of West Potomac Avenue about 12:20 a.m., officials said.
Alex Lyon stopped all 28 shots in the 4-0 victory in Game 5
State Sen. Darren Bailey had been seeking Trump’s endorsement for months. The downstate farmer met with Trump last year and attended a fundraiser in April in which he snapped a photo with the former president.
Offense has scored three runs in its last three losses to the Orioles, who entered Saturday’s game with a 4.10 ERA - 12th in the AL